Literature DB >> 20714944

Serum cytokine levels in patients with advanced non-small cell lung cancer: correlation with treatment response and survival.

Chunxia Su1, Caicun Zhou, Songwen Zhou, Jianfang Xu.   

Abstract

To investigate whether expression of several cytokines affected clinical outcome in non-small cell lung cancer patients. A total of 86 stage IIIB/IV non-small cell lung cancer patients, treated with platinum-based doublets, were examined expression levels of IL-1, IL-2R, IL-5, IL-6, IFN-γ, TNF-α pre- and post-chemotherapy. Enzyme-linked immunosorbent assay technique was performed. Kaplan-Meier analysis and Cox regression analyses were used to adjust for possible confounding variables. IL-6 expression levels were significantly decreased due to chemotherapy in patients with stable disease (P=0.041). IL-2R expression levels were significantly increased due to chemotherapy in patients with progression disease (P=0.010). Patients with high concentrations of TNF post-chemotherapy had a significantly longer survival (P=0.009, 17 months versus 11 months) than low levels. Multivariate analysis showed that sex, response rate, IL-1 and TNF-α were significantly predictive of the survival. Serum IL-6 and IL-2R levels correlated with chemoresponse in advanced non-small cell lung cancer, serum IL-1 and TNF-α can be predictive factors in advanced non-small cell lung cancer.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20714944     DOI: 10.1007/s12032-010-9645-6

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  15 in total

1.  Genetic variation in the DNA repair genes is predictive of outcome in lung cancer.

Authors:  Athena Matakidou; Rachid el Galta; Emily L Webb; Matthew F Rudd; Helen Bridle; Tim Eisen; Richard S Houlston
Journal:  Hum Mol Genet       Date:  2007-10-01       Impact factor: 6.150

2.  Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer.

Authors:  G V Scagliotti; F De Marinis; M Rinaldi; L Crinò; C Gridelli; S Ricci; E Matano; C Boni; M Marangolo; G Failla; G Altavilla; V Adamo; A Ceribelli; M Clerici; F Di Costanzo; L Frontini; M Tonato
Journal:  J Clin Oncol       Date:  2002-11-01       Impact factor: 44.544

3.  Serum vascular endothelial growth factor (VEGF) and interleukin-8 (IL-8) levels in small cell lung cancer.

Authors:  Faruk Tas; Derya Duranyildiz; Hilal Oguz; Hakan Camlica; Vildan Yasasever; Erkan Topuz
Journal:  Cancer Invest       Date:  2006 Aug-Sep       Impact factor: 2.176

4.  Circulating angiogenic cytokines in patients with advanced non-small cell lung cancer: correlation with treatment response and survival.

Authors:  Arkadiusz Z Dudek; Hemchandra Mahaseth
Journal:  Cancer Invest       Date:  2005       Impact factor: 2.176

5.  [Prognostic factors in patients with stage III and IV non-small cell lung cancer].

Authors:  Li-hua Song; Xian-rang Song; Mei-qin Liu; Xi-qin Zhang; Li Zheng; Xiu-ju Li; Pu-xiang Liu
Journal:  Zhonghua Zhong Liu Za Zhi       Date:  2004-06

Review 6.  [Clinical significance of interleukin-6 (IL-6) as a prognostic factor of cancer disease].

Authors:  Marta Łukaszewicz; Barbara Mroczko; Maciej Szmitkowski
Journal:  Pol Arch Med Wewn       Date:  2007 May-Jun

Review 7.  [The value of measuring the serum level of soluble interleukin-2 receptors in lung cancer patients].

Authors:  Alicja Siemińska
Journal:  Pol Merkur Lekarski       Date:  2004-02

Review 8.  Gene expression and polymorphisms of DNA repair enzymes: cancer susceptibility and response to chemotherapy.

Authors:  Carlos Camps; Rafael Sirera; Vega Iranzo; Miquel Tarón; Rafael Rosell
Journal:  Clin Lung Cancer       Date:  2007-05       Impact factor: 4.785

9.  Serum interleukin-6 level but not genotype predicts survival after resection in stages II and III gastric carcinoma.

Authors:  Wei-Chih Liao; Jaw-Town Lin; Chun-Ying Wu; Shih-Pei Huang; Ming-Tsan Lin; Ariel Sing-Huei Wu; Yu-Jie Huang; Ming-Shiang Wu
Journal:  Clin Cancer Res       Date:  2008-01-15       Impact factor: 12.531

10.  Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy.

Authors:  Wei Zhou; Sarada Gurubhagavatula; Geoffrey Liu; Sohee Park; Donna S Neuberg; John C Wain; Thomas J Lynch; Li Su; David C Christiani
Journal:  Clin Cancer Res       Date:  2004-08-01       Impact factor: 12.531

View more
  11 in total

1.  Modulation of peripheral immune responses by paclitaxel-ifosfamide-cisplatin chemotherapy in advanced non-small-cell lung cancer.

Authors:  Nikolaos Koufos; Despina Michailidou; Ioannis D Xynos; Periclis Tomos; Kalliopi Athanasiadou; Christos Kosmas; Nikolaos Tsavaris
Journal:  J Cancer Res Clin Oncol       Date:  2013-09-26       Impact factor: 4.553

2.  Interleukin-6 but not tumour necrosis factor-alpha predicts survival in patients with advanced cancer.

Authors:  Sang-Yeon Suh; Youn Seon Choi; Chang Hwan Yeom; Sang Mi Kwak; Ho Min Yoon; Dae Gyun Kim; Su-Jin Koh; Jeanno Park; Myung Ah Lee; Yong Joo Lee; Ah-Ram Seo; Hong-Yup Ahn; Eunji Yim
Journal:  Support Care Cancer       Date:  2013-07-05       Impact factor: 3.603

3.  Prediagnostic nonsteroidal anti-inflammatory drug use and lung cancer survival in the VITAL study.

Authors:  Theodore M Brasky; Christina S Baik; Christopher G Slatore; Mariela Alvarado; Emily White
Journal:  J Thorac Oncol       Date:  2012-10       Impact factor: 15.609

4.  Preclinical evaluation of 4-[3,5-bis(2-chlorobenzylidene)-4-oxo-piperidine-1-yl]-4-oxo-2-butenoic acid, in a mouse model of lung cancer xenograft.

Authors:  Vivek R Yadav; Kaustuv Sahoo; Vibhudutta Awasthi
Journal:  Br J Pharmacol       Date:  2013-12       Impact factor: 8.739

5.  Predictive and prognostic value of LPS-stimulated cytokine secretion in metastatic non-small cell lung cancer.

Authors:  P J Vlachostergios; I Gioulbasanis; S Ghosh; C Tsatsanis; G Papatsibas; A Xyrafas; E Hatzidaki; C Vasiliou; K Kamposioras; S Agelaki; A N Margioris; D Nasi; V Georgoulias; C N Papandreou
Journal:  Clin Transl Oncol       Date:  2013-03-05       Impact factor: 3.405

6.  TNFRSF1B +676 T>G polymorphism predicts survival of non-small cell lung cancer patients treated with chemoradiotherapy.

Authors:  Xiaoxiang Guan; Zhongxin Liao; Hongxia Ma; Ji Qian; Zhensheng Liu; Xianglin Yuan; Daniel Gomez; Ritsuko Komaki; Li-E Wang; Qingyi Wei
Journal:  BMC Cancer       Date:  2011-10-14       Impact factor: 4.430

7.  Differential response of head and neck cancer cell lines to TRAIL or Smac mimetics is associated with the cellular levels and activity of caspase-8 and caspase-10.

Authors:  N Raulf; R El-Attar; D Kulms; D Lecis; D Delia; H Walczak; K Papenfuss; E Odell; M Tavassoli
Journal:  Br J Cancer       Date:  2014-10-14       Impact factor: 7.640

8.  High systemic IL-6 is associated with worse prognosis in patients with non-small cell lung cancer.

Authors:  Estela Maria Silva; Vânia Sammartino Mariano; Paula Roberta Aguiar Pastrez; Miguel Cordoba Pinto; António Gil Castro; Kari Juhani Syrjanen; Adhemar Longatto-Filho
Journal:  PLoS One       Date:  2017-07-17       Impact factor: 3.240

Review 9.  Cytokine patterns in cancer patients: A review of the correlation between interleukin 6 and prognosis.

Authors:  Bodo E Lippitz; Robert A Harris
Journal:  Oncoimmunology       Date:  2016-05-11       Impact factor: 8.110

10.  Association of inflammatory biomarkers with lung cancer in North Indian population.

Authors:  Priyanka Gaur; Sandeep Bhattacharya; Surya Kant; Ras Kushwaha; Rajiv Garg; Gaurav Singh; Sarika Pandey; Supriya Sharma
Journal:  Afr Health Sci       Date:  2019-06       Impact factor: 0.927

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.